GlassScriptPhysician profile
Timothy Miller Ullmann
NPI 1992123194
$862.50
in general payments reported to CMS, 2019-2025
10 companies · $572 in 2025
The $572 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $11.66 · 2023: $116 · 2024: $163 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $217.10 | 2025 | Omnipod |
| Dexcom, INC. | $175.49 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $166.58 | 2022-2025 | Mounjaro, Jardiance |
| Radius Health, INC. | $128.27 | 2023-2024 | |
| Ascensia Diabetes Care US INC. | $53.43 | 2024 | |
| Alexion Pharmaceuticals, INC. | $36.40 | 2023 | Strensiq |
| Madrigal Pharmaceuticals | $34.82 | 2025 | Rezdiffra |
| Pfizer INC. | $17.39 | 2023 | |
| Abbott Laboratories | $16.79 | 2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $16.23 | 2025 | Licart, Flector, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Ullmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.